Crippling hunger has driven Vitola Genti to the brink. The 67-year-old, a refugee in Malawi, has HIV and is dependent on antiretroviral drugs to keep the virus dormant in her body.

The Communities Delegation to the Unitaid Board is currently inviting applications for membership from people living with HIV, affected by TB, malaria and those co-infected with HIV and HCV for the period 2023-2025. The Delegation would like to increase its representativity by recruiting additional members from under-represented countries and disease areas.

Public Health Action is the peer-reviewed open access journal of The International Union Against Tuberculosis and Lung Disease. It communicates and reports new knowledge across all relevant areas of operational research including: infection control, nutrition, TB, HIV, vaccines, smoking, COVID-19, microbial resistance and disease outbreaks.

The World Health Organization (WHO) is seeking experts to serve as members of the Technical Advisory Group on dosing of TB medicines for adults and children. For further details about the advisory group, the expert profiles being sought, the process for experts to express interest, and the process of selection, click here.

Rising CD4 counts and suppressed viral load on antiretroviral treatment have had a far greater impact on reducing new cases of tuberculosis (TB) in people with HIV in Switzerland than testing and preventive treatment for latent TB, researchers from the Swiss HIV Cohort report in the journal Clinical Infectious Diseases.

In the first global assessment of TB among incarcerated people, a new study found consistently high TB case rates and low case detection in prisons, suggesting the need for health organizations to increase efforts to reduce the spread of TB among this high-risk population.

Mortality risk was higher for patients with concurrent diabetes and TB infection and more common than HIV and TB coinfection.

The Stop TB Partnership launches the Challenge Facility for Civil Society Round 12 with USD 13.5 million in funding for civil society and communities from high TB burden countries.

In the face of growing antibiotic resistance among bacterial infections, scientists at The Hospital for Sick Children (SickKids) have delved into the molecular science behind treatment-resistant tuberculosis.

KIT and Research Center Borstel present nanoparticles with a high antibiotic concentration for inhalation – nanocarriers of antibiotics can reduce resistances and enhance compatibility